Yvonne McGrath's Insider Trades & SAST Disclosures
Yvonne McGrath's most recent trade in ITeos Therapeutics Inc was a trade of 91,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Yvonne McGrath.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ITeos Therapeutics Inc | Yvonne McGrath | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 91,000 | 91,000 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 15,300 | 46,300 | - | 0 | Common Stock | |
| ITeos Therapeutics Inc | Yvonne McGrath | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 153,600 | 153,600 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | McGrath Yvonne | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 31,000 | 31,000 | - | 0 | Common Stock | |
| ITeos Therapeutics Inc | Yvonne McGrath | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 10,000 | 85,123 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.24 per share. | 01 Mar 2022 | 10,000 | 10,000 | - | 4.2 | 42,400 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.76 per share. | 01 Mar 2022 | 10,000 | 0 | - | 36.8 | 367,570 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 08 Jun 2021 | 7,927 | 0 | - | 20 | 158,540 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 7,927 | 95,123 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.23 per share. | 08 Jun 2021 | 7,927 | 7,927 | - | 4.2 | 33,531 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.23 per share. | 01 Jun 2021 | 7,604 | 7,604 | - | 4.2 | 32,165 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 7,604 | 103,373 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Sale of securities on an exchange or to another person at price $ 20.18 per share. | 01 Jun 2021 | 7,604 | 0 | - | 20.2 | 153,443 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 323 | 103,050 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 01 Jun 2021 | 323 | 0 | - | 20 | 6,460 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.23 per share. | 01 Jun 2021 | 323 | 323 | - | 4.2 | 1,366 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 24 May 2021 | 7,927 | 0 | - | 21.9 | 173,796 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2021 | 7,927 | 110,977 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.23 per share. | 24 May 2021 | 7,927 | 7,927 | - | 4.2 | 33,531 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.23 per share. | 17 May 2021 | 7,926 | 7,926 | - | 4.2 | 33,527 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2021 | 7,926 | 118,904 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Sale of securities on an exchange or to another person at price $ 24.41 per share. | 17 May 2021 | 5,807 | 2,119 | - | 24.4 | 141,777 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Sale of securities on an exchange or to another person at price $ 25.43 per share. | 17 May 2021 | 2,029 | 90 | - | 25.4 | 51,602 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Sale of securities on an exchange or to another person at price $ 26.01 per share. | 17 May 2021 | 90 | 0 | - | 26.0 | 2,341 | Common Stock |
| ITeos Therapeutics Inc | Yvonne McGrath | VP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges